Clovis Oncology (CLVS) Falls: Stock Goes Down 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 7:36AM CDT
Clovis Oncology fell over 5% in the last trading session, reversing its recent trend
BIIB: 423.57 (+1.46), CLVS: 85.04 (-1.36)
Where Are The Investors Headed: Complementary Research on Clovis Oncology, DBV Technologies, Cleveland BioLabs, Arrowhead Research and Athenahealth
PR Newswire - Fri Apr 17, 7:25AM CDT
Editor Note: For more information about this release, please scroll to bottom.
DBVT: 25.66 (-0.01), ARWR: 6.88 (+0.14), CLVS: 85.04 (-1.36), CBLI: 3.20 (+0.01), ATHN: 120.16 (-1.35)
Healthcare ratings roundup
Seeking Alpha - at Seeking Alpha - Wed Apr 15, 12:32PM CDT
ICEL: 16.47 (-0.02), ARWR: 6.88 (+0.14), CLVS: 85.04 (-1.36), UNH: 117.81 (-1.47), ABBV: 64.52 (+0.91), NUVA: 43.38 (+0.10)
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 14, 4:58PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
HTBX: 7.71 (-0.64), DOVR: 8.42 (-0.02), STCK: 18.52 (-0.02), CLVS: 85.04 (-1.36), ORMP: 7.25 (-0.10), BIND: 7.01 (-0.30), EGRX: 60.53 (+1.22), VLTC: 15.14 (-1.04), BCLI: 4.29 (-0.09), REPH: 10.71 (-0.78)
Critical Alerts For JP Morgan Chase, Builders FirstSource, Netflix, Clovis Oncology and Ruby Tuesday Released By InvestorsObserver
PR Newswire - Tue Apr 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for JPM, BLDR, NFLX, CLVS and RT.
NFLX: 557.68 (-2.76), RT: 7.25 (-0.07), JPM: 62.94 (+0.63), CLVS: 85.04 (-1.36), BLDR: 13.00 (-0.09)
Clovis Technology Gets Big Boost From Goldman Upgrade
at Investor's Business Daily - Mon Apr 13, 3:06PM CDT
Clovis Technology (CLVS) stock rose Monday after Goldman Sachs upgraded its rating and sharply raised its stock price target on the developer of anti-cancer treatments. Goldman upgraded Clovis to a buy from neutral and increased the price target to...
CLVS: 85.04 (-1.36)
Why Clovis Oncology, Inc. Is Soaring Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 13, 11:26AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Clovis Oncology rallied by...
CLVS: 85.04 (-1.36)
Clovis Oncology heads north on Goldman's higher price target
Seeking Alpha - at Seeking Alpha - Mon Apr 13, 11:18AM CDT
CLVS: 85.04 (-1.36)
Clovis Oncology (CLVS) Stock Spikes Today on Analyst Upgrade
at The Street - Mon Apr 13, 10:22AM CDT
Clovis Oncology (CLVS) shares are up double digits after having its price target raised by analysts at Goldman Sachs.
CLVS: 85.04 (-1.36)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Apr 13, 8:15AM CDT
FRO: 2.77 (-0.20), GBSN: 4.98 (+1.44), P: 17.51 (+0.28), CLVS: 85.04 (-1.36), ARWR: 6.88 (+0.14), ORMP: 7.25 (-0.10), BLDR: 13.00 (-0.09), IFON: 2.73 (+0.13)
Clovis Oncology (CLVS) in Focus: Stock Moves 8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 8:46AM CDT
Clovis Oncology (CLVS) was a big mover last session, with shares rising almost 8% on the day.
CLVS: 85.04 (-1.36), AFFX: 12.57 (-0.13)
Critical Alerts For Celgene, Twitter, Clovis Oncology, BHP Billiton and Brown-Forman Released By InvestorsObserver
PR Newswire - Wed Apr 08, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CELG, TWTR, CLVS, BHP and BF.B.
CLVS: 85.04 (-1.36), BHP: 47.80 (+1.55), TWTR: 51.73 (+0.41), BF.B: 92.65 (-0.66), CELG: 115.54 (+0.72)
Clovis Oncology's Rucaparib Gets Breakthrough Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 07, 5:01PM CDT
Clovis Oncology, Inc.'s (CLVS) rucaparib received Breakthrough Therapy status from the FDA as monotherapy for advanced ovarian cancer.
CYTK: 7.29 (-0.09), CLVS: 85.04 (-1.36), ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10)
Why Clovis Oncology Shares Soared Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 07, 3:53PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Clovis Oncology vaulted...
CLVS: 85.04 (-1.36)
Clovis Cancer 'Breakthrough,' Oculus Flop Top Biotech News Late
at Investor's Business Daily - Mon Apr 06, 6:19PM CDT
Clovis Oncology (CLVS) shares rose in after-hours trading on ovarian cancer news, one of several notable biotech announcements late Monday. Clovis announced that the Food and Drug Administration has given its rucaparib agent as a "breakthrough...
BCRX: 10.62 (-0.09), CLVS: 85.04 (-1.36), SHPG: 253.58 (+3.70), PRTA: 36.96 (+0.36), DYAX: 28.12 (+0.15), OCUL: 25.90 (-0.05)
CLOVIS ONCOLOGY
at Investor's Business Daily - Mon Apr 06, 5:41PM CDT
CLOVIS ONCOLOGY (CLVS) said that the FDA gave "breakthrough therapy" status to rucaparib, its ovarian cancer treatment. Shares rose 6.9% to 73.40.
CLVS: 85.04 (-1.36)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 4:35PM CDT
BTU: 4.87 (+0.06), CLVS: 85.04 (-1.36), OCN: 7.68 (+0.14), NUS: 56.99 (+0.06), VNCE: 19.10 (-0.08), NRZ: 16.96 (-0.04), GEL: 47.60 (-0.90), DYAX: 28.12 (+0.15), MT: 9.63 (+0.22), ARO: 3.40 (+0.05)